Immunomedics Inc (IMMU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats.
The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights Immunomedics Inc (Immunomedics) is a clinical-stage bio-pharmaceutical company that researches, develops, manufactures and commercializes monoclonal antibody-based drugs for the treatment of cancer and autoimmune disorders.The company develops its candidates based on its proprietary technologies namely, ADC Linker technology and Dock-And-Lock platform.
Its lead product candidate is Sacituzumab govitecan (IMMU-132) in Phase II development stage received breakthrough therapy designation from the US FDA for the treatment of patients with metastatic triple-negative breast cancer and metastatic solid cancers.Immunomedics’ other lead product candidates include Labetuzumab Govitecan (IMMU-130) and Epratuzumab.
It also has other product candidates that target solid tumors, hematologic malignancies and other diseases, in various stages of clinical and pre-clinical development.The company also manufactures and commercializes diagnostic imaging product named, LeukoScan.
Immunomedics is headquartered in Morris Plains, New Jersey, the US.
Immunomedics Inc Key Recent Developments Aug 28,2018: Immunomedics Announces Participation in Upcoming Healthcare Conferences Aug 23,2018: Immunomedics announces fourth quarter and fiscal year 2018 results and provides corporate update May 09,2018: Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update Apr 09,2018: Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer Feb 08,2018: Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update
Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Our reports have been used by over 10K customers, including:
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 184.108.40.206) - Pipeline Review, H2 2018 Summary Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 220.127.116.11) pipeline Target constitutes close to 26 molecules. The latest report Tyrosine Protein Kinase...
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 18.104.22.168) - Pipeline Review, H2 2018 Summary Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 22.214.171.124) - Phenylalanine 4 hydroxylase or Phenylalanine hydroxylase (PAH) is an enzyme that catalyzes the hydroxylation of the...
Bone Metastasis - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H2 2018, provides an overview of the Bone Metastasis (Oncology) pipeline landscape. Bone metastasis occurs when cancer cells...
Optic Nerve Disorders Drug Development Pipeline Review, 2018 Summary Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 10 products in development for this indication. Glaucoma is a disease of...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.